The standard of practice for HER2/neu-positive breast cancer is 1 year of adjuvant trastuzumab with chemotherapy.13 However, shorter regimens that consist of 9 weeks of trastuzumab with chemotherapy have been reported from Finland and are considered highly cost effective.14 This protocol is being adopted by most African physicians because of cost constraints. The gene discussed is ERBB2; the disease is breast carcinoma.